Why Is the Gaudium IVF IPO Attracting Immediate Market Attention?
The Gaudium IVF & Women Health IPO opened for subscription on February 20, 2026, and early participation indicates measured but visible investor interest. Within hours of opening, the ₹165 crore issue was booked 34%, with retail investors driving initial demand.
Priced in the band of ₹75–79 per share, the IPO values the company at approximately ₹575 crore at the upper end. The public issue will close on February 24, and listing is scheduled for February 27 on both NSE and BSE.
Ahead of the public bidding, the company raised ₹49.5 crore from anchor investors, which often provides early confidence in the issue structure and pricing discipline.
What Does the Subscription Trend Reveal About Day 1 Sentiment?
The IPO witnessed 20% subscription within the first 30 minutes, which later climbed to 34% during early trading hours. Retail participation led the initial traction, while non-institutional and qualified institutional buyers are expected to build positions closer to closing day.
In other mid-sized IPOs, retail demand usually rises first, and then institutional bidding happens in the last few days of subscription. In categories like QIB and NII, crossing significant oversubscription ratios is usually a good sign that a listing will do well.
How Is Gaudium IVF IPO GMP Reflecting Pre-Listing Sentiment?
The latest Gaudium IVF IPO GMP today stands at ₹8.5, implying an estimated grey market price of around ₹87.5 compared to the upper issue price of ₹79. This translates into a potential 10.76% listing premium.
Earlier, the grey market premium had reached ₹15 before moderating. A declining GMP does not necessarily indicate weakening fundamentals; it often reflects normalization after early speculative enthusiasm.
It's important to remember that the grey market premium is not an official measure of sentiment and does not guarantee how well a listing will do. But when premiums stay above the issue price for a long time, it usually means that people in the market have positive views before the listing.
What Are the Complete Offer and Financial Details Investors Should Evaluate?
The IPO consists of a fresh issue of 1.14 crore equity shares and an offer for sale of nearly 95 lakh shares by promoter Manika Khanna. Proceeds from the fresh issue are intended for expansion, debt reduction and general corporate purposes.Key IPO & Financial Snapshot
Revenue increased from ₹47.89 crore in FY24 to ₹70.72 crore in FY25, marking significant growth. Profit after tax nearly doubled, moving from ₹10.31 crore to ₹19.13 crore. The half-year performance to September 2025 continued this trend.
At the upper band, valuation is roughly 28–30 times FY25 earnings, which some analysts describe as premium given the company’s growth path and sector positioning.
Who Backed the IPO in the Anchor Round?
The company allotted 62,65,860 shares at ₹79 per share, aggregating to ₹49.5 crore, to anchor investors including MERU Investment Fund PCC-CELL, Sanshi Fund I, Hornbill Orchid India Fund and Carnelian India Multi Strategy Fund. Strong anchor participation often enhances confidence in the pricing range and demand structure.
How Is Gaudium IVF Positioned Within the Healthcare Segment?
Gaudium IVF operates through a hub-and-spoke model with seven hubs and 28 spokes across multiple Indian states. IVF, ICSI, IUI, genetic testing, fertility preservation, and advanced gynecological support are some of the services it offers. The company also treats patients from other countries, like Canada, the UK, the US, Kenya, South Africa, and Oman. This shows that there is a demand for its services around the world.
Proceeds from the fresh issue will be deployed toward establishing 19 new IVF centres, expanding geographic coverage and capacity in underserved regions. Gaudium IVF is the first IPO in India that focuses on fertility, which puts it in a unique position that could draw investors to the healthcare sector.
What Are the Real Risks and Valuation Considerations?
While early subscription momentum and GMP trends suggest constructive sentiment, valuation should be evaluated carefully. A multiple of around 28–30x forecast earnings at the upper band places the issue in a premium bracket relative to some healthcare peers.
Analysts have flagged a ₹31 crore tax dispute as a risk to monitor, and execution risk tied to aggressive expansion plans remains a factor for long-term performance.
The performance of a short-term listing depends on how strong the subscriptions are and how liquid the market is in general. Long-term returns will depend on how well the listing can execute and how fast the sector is growing.
What Should Investors Consider Before Deciding?
Because IPO valuation, subscription analysis, and grey market interpretation are all very complicated, it's important to look at offerings with structured insight instead of guesswork.
For investors seeking to sharpen their analytical skills, understand market valuation frameworks and build disciplined investment approaches in the primary market, ICFM India offers comprehensive training modules on IPO evaluation, risk management, market analytics and capital allocation strategies. This educational support helps investors avoid common pitfalls and make data-driven decisions during high-volatility listing environments.
Engaging with structured learning resources can improve confidence, reduce emotional bias and support more informed participation in upcoming IPOs.
Final Market Perspective
The Gaudium IVF IPO LIVE updates reflect meaningful early activity, with a 34% subscription on Day 1 and an implied 10–11% grey market premium. As the subscription window moves closer to the February 24 close, investors will closely track category-wise demand and institutional participation.
Ultimately, the February 27 listing will provide the first complete market signal on debut pricing and demand realization.
Frequently Asked Questions
Why is Gaudium IVF IPO trending today?
Gaudium IVF IPO is trending because the issue opened for subscription on February 20 and was booked 34% within the first few hours of Day 1. Investors are actively tracking subscription status, anchor participation and the current grey market premium ahead of the February 27 listing.
What is the Gaudium IVF IPO GMP today?
The Gaudium IVF IPO GMP today is ₹8.5. At the upper price band of ₹79, this indicates an implied grey market price of around ₹87.5, suggesting a potential listing premium of approximately 10–11%. Grey market premium is an unofficial indicator and may change based on demand and market sentiment.
How much is the Gaudium IVF IPO price band?
The Gaudium IVF IPO price band is fixed at ₹75–79 per share. At the upper end of the band, the company is valued at approximately ₹575 crore.
How much has Gaudium IVF IPO been subscribed so far?
On Day 1, the Gaudium IVF IPO was booked 34% in early hours. The issue saw 20% subscription within the first 30 minutes of opening, with retail investors leading the initial demand.
What is the total issue size of Gaudium IVF IPO?
The total issue size of Gaudium IVF IPO is ₹165 crore. The offering includes a fresh issue of 1.14 crore equity shares and an offer for sale of nearly 95 lakh shares by the promoter.
Who are the anchor investors in Gaudium IVF IPO?
Gaudium IVF raised ₹49.5 crore from anchor investors before the public issue opened. Anchor participants include MERU Investment Fund PCC-CELL, Sanshi Fund I, Hornbill Orchid India Fund and Carnelian India Multi Strategy Fund.
When will Gaudium IVF IPO close and list?
The IPO will close for subscription on February 24, 2026. The shares are scheduled to list on February 27, 2026, on both NSE and BSE.
How strong are Gaudium IVF’s financials?
For FY25, the company reported revenue of ₹70.72 crore and profit after tax of ₹19.13 crore, compared to ₹47.89 crore revenue and ₹10.31 crore PAT in FY24. For the half-year ended September 2025, total income stood at ₹49.5 crore with ₹12.5 crore PAT.
Is Gaudium IVF IPO valuation considered premium?
At the upper price band of ₹79, the IPO is valued at approximately 28–30 times FY25 earnings. Some analysts describe the valuation as relatively premium, but supported by growth in the fertility care segment.
What should investors monitor before listing?
Before the listing date, investors usually keep an eye on the final subscription ratios, the number of oversubscribed categories, the number of institutional investors, changes in the grey market premium, and the overall liquidity of the market.
